Order Sermorelin Acetate Online
Sermorelin Acetate (GHRH) is a bio-identical hormone that has recently been genetically engineered to stimulate the secretion of Growth Hormone Releasing Hormone (GHRH) from the hypothalamus, a gland adjacent to the pituitary gland. GHRH is a peptide that contains the first 29 amino acids of our own GH. These 29 amino acids are the active amino acids of GHRH. It is GHRH that stimulates the pituitary glands to release GH. As we get older, the hormones produced by the anterior pituitary are depleted. It has now been shown that GHRH can restore the GH-RNA to a youthful level causing elevation of levels of IGF-1
Purchase Sermorelin Acetate Online
Sermorelin Acetate, also known as GRF 1-29, is a Growth Hormone Releasing Hormone (GHRH) produced by the brain that stimulates the production and release of Growth Hormone (GH). Sermorelin was first developed in the 70s, which is thought to be the shortest fully functional fragment of GHRH and has been used as a test for Growth Hormone secretion. It is often used extensively in Anti-aging Therapy along with Testosterone in men. Sermorelin affects a more primary source of failure in the GH neuroendocrine axis, has more physiological activity, and its use for adult hormone deficiency is not restricted. Compared to human Growth Hormone (hGH), Sermorelin Acetate is a growth hormone secretagogue, which means that it stimulates the pituitary gland to produce and secrete growth hormone. Also, Sermorelin Acetate and Modified GRF 1-29 contains 29 amino acids whereas hGH is a larger molecule containing 191 amino acids. Sermorelin acetate is a human growth hormone-releasing hormone (GHRH or GRF) used for diagnostic evaluation of pituitary function and also for increasing growth in children. Off label usage of sermorelin acetate may include acute or age-related growth hormone insufficiency. Sermorelin acetate is discontinued; generic versions may be available.
Buy Sermorelin Acetate Online
Unlike rhGH which has legal restrictions on its clinical use, the off-label prescribing of sermorelin is not prohibited by federal law. Thus, it can be carefully employed and evaluated by the practitioner to objectively determine whether it provides greater benefits with less risk to his/her patients. In support of this effort, the Society for Applied Research in Aging will be providing sermorelin free of cost on a competitive basis to practitioners willing to study its effects under protocol conditions and to report the outcomes in a peer-reviewed journal such as Clinical Interventions in Aging. Hopefully, through such efforts we can contribute to development of a paradigm for evidence-based GHRT in clinical age management.